Allergios – We see allergy.

Allergios’ direct allergy diagnosis
enables patients to be better
informed and effectively treated

The Challenge

Allergy is among the most common chronic diseases worldwide. Up to 20% of patients with allergies live with a severe debilitating form of their condition, and struggle daily with the fear of a possible asthma attack, anaphylactic shock, or even death from an allergic reaction (EAACI, 2016).

Current tests to diagnose allergy such as the skin prick test and the IgE blood tests, indicate sensitisation to allergens, but not necessarily an allergic response. These tests are in the majority of cases not indicative of an actual allergy.

Our Solution

Researchers from the University of Bremen, supported by colleagues at the Medical University of Vienna, have developed a method and system that can directly diagnose allergies by visualising the allergic response:

the ability of immunological factors in patient blood to induce degranulation of basophils in the presence of allergen

The system consists of a disposable microfluidic chip and an optical reader, supported by software running the analysis.
The test delivers the necessary information about the patient’s allergy status and enables doctors to provide the best suited treatment timely.

We see allergy

Our Core Team

Prof. Michael Vellekoop

Inventor

Co-Founder

Dr. Sander van den Driesche

Chief Technical Officer & Inventor

Co-Founder

Folkert Roossien

Chief Development Officer

Co-Founder

Ernst Elhorst

Chief Executive Officer

Co-Founder

Advisory Board

Prof. Dr. Heimo Breiteneder

World-renowned expert on the molecular biology of allergens

Inventor

Dr. Christine Hafner

Clinical allergist and dermatologist with a focus on molecular allergy diagnostics

Inventor

Dr. Claas Falldorf

BIAS Germany

Inventor

Ronald Zegger

NLC

Venture Partner

Company update

Allergios is currently in the process of perfecting its solution, as well as validating in real clinical settings. A new proprietary camera system has been developed and is being tested with patients’ blood samples material.

At the same time, Allergios has successfully closed its latest round of seed financing in April 2022. Oversubscribed, this financial injection is proof of the ongoing support for our innovation and will enable us to take our development to the clinical trial stage. The trial itself, for which we are now seeking funding, is planned for end 2023 / early 2024.

If you want to contribute to the success of Allergios in any way, send us a message with the contact form below and we will get back to you. You can also submit your details if you want us to keep you updated on our developments.

Contact us

"*" indicates required fields

info@allergios.health